# US 2021/0277359 A1 · Cell and tissue models comprising fibroblasts of the dermo-hypodermic junction and applications thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0277359 A1
- Document ID: US20210277359A1
- Status: Published application
- Kind: A1
- Application number: 16/973,916
- Filed: 2019-07-01
- Published: 2021-09-09
- Earliest claimed: 2018-06-29
- Assignees: L'oreal
- Applicants: L'oreal
- Inventors: Valérie HAYDONT
- Web page: https://patentgrep.com/patent/US20210277359A1

## CPC

- C12N 5/0625: {Epidermal cells, skin cells; Cells of the oral mucosa}
- C12N 5/0656: {Adult fibroblasts}
- C12N 5/0653: {Adipocytes; Adipose tissue}
- C12N 5/0654: {Osteocytes, Osteoblasts, Odontocytes; Bones, Teeth}
- C12N 5/0655: {Chondrocytes; Cartilage}
- C12N 5/0698: {Skin equivalents}
- C12Q 1/6881: for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
- C12N 2503/06: Screening or testing on artificial skin
- C12N 2506/1307: from adult fibroblasts
- C12N 2533/54: Collagen; Gelatin
- C12N 2535/00: Supports or coatings for cell culture characterised by topography
- C12Q 2600/158: Expression markers
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present invention relates to an in vitroprocess for preparing cell and tissue models comprising at least one step of culturing fibroblasts of the dermo-hypodermic junction; the models obtained and also the implementation thereof in processes for screening active agents that promote the differentiation of fibroblasts of the dermo-hypodermic junction into adipocyte, osteoblast and/or chondroblast cells.

## Claims

### Claim 1

An in vitro process for preparing a cell model comprising at least one step of culturing fibroblasts of the dermo-hypodermic junction.

### Claim 2 (depends on 1)

The process as claimed in claim 1, wherein the fibroblasts are cultured between 24 h and 72 h after reaching at least 80% confluence.

### Claim 3 (depends on 1)

The process as claimed in claim 1, also comprising a step of centrifugation of the fibroblasts obtained at the end of said culture step.

### Claim 4

An in vitro process for preparing a tissue model comprising at least one step of culturing fibroblasts of the dermo-hypodermic junction on collagen sponge.

### Claim 5 (depends on 4)

The process as claimed in claim 4, wherein said fibroblasts are cultured for 10 to 20 days.

### Claim 6 (depends on 1)

The in vitro process for preparing a cell model as claimed in claim 1 or an in vitro process for preparing a tissue model comprising at least one step of culturing fibroblasts of the dermo-hypodermic junction, also comprising a step of identification of a dermal fibroblast as a fibroblast of the dermo-hyperdermic junction, said identification step being prior to said culture step and comprising:
a) providing a biological sample comprising at least one dermal fibroblast,
b) measuring, in the biological sample provided in step a), the level of an expression product of at least one gene selected from the group consisting of the genes UCP2, ACAN, FGF9 and COL11A1, and the level of an expression product of the gene KLF9,
c) identifying the dermal fibroblast of step a) as a fibroblast of the dermo-hypodermic junction when:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 7 (depends on 1)

An in vitro cell model obtainable according to the process as defined in claim 1.

### Claim 8 (depends on 4)

An in vitro tissue model obtainable according to claim 4.

### Claim 9 (depends on 7)

The cell model as claimed in claim 7 or tissue model obtainable by an in vitro process comprising at least one step of culturing fibroblasts of the dermo-hypodermic junction on collagen sponge, comprising fibroblasts of the dermo-hypodermic junction for which:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 10 (depends on 7)

The use of in vitro cell or tissue models as defined in claim 7 as tool for screening for active agents that promote the differentiation of fibroblasts of the dermo-hypodermic junction into adipocyte, osteoblast and/or chondroblast cells.

### Claim 11 (depends on 7)

A process for screening active agents that promote the differentiation of fibroblasts of the dermo-hypodermic junction into adipocyte, osteoblast and/or chondroblast cells, comprising the following steps:
i. providing a cell as defined in claim 7,
ii. bringing said model into contact with at least one agent to be screened,
iii. carrying out a qualitative and/or quantitative measurement of the expression of at least one marker of the adipocyte, osteoblast and/or chondrocyte cells or of their biological activity (activities), then
iv. comparing the measurement carried out in step iii) with that obtained from a control.

### Claim 12 (depends on 8)

A process for screening active agents that promote the differentiation of fibroblasts of the dermo-hypodermic junction into adipocyte, osteoblast and/or chondroblast cells, comprising the following steps:
i. providing a as defined in claim 8,
ii. bringing said model into contact with at least one agent to be screened,
iii. carrying out a qualitative and/or quantitative measurement of the expression of at least one marker of the adipocyte, osteoblast and/or chondrocyte cells or of their biological activity (activities), then
iv. comparing the measurement carried out in step iii) with that obtained from a control.

### Claim 13 (depends on 1)

The process as claimed in claim 1, wherein the fibroblasts are cultured for 48 h after reaching at least 80% confluence.

### Claim 14 (depends on 2)

The process as claimed in claim 2, also comprising a step of centrifugation of the fibroblasts obtained at the end of said culture step.

### Claim 15 (depends on 2)

The in vitro process for preparing a cell model as claimed in claim 2, also comprising a step of identification of a dermal fibroblast as a fibroblast of the dermo-hyperdermic junction, said identification step being prior to said culture step and comprising:
a) providing a biological sample comprising at least one dermal fibroblast,
b) measuring, in the biological sample provided in step a), the level of an expression product of at least one gene selected from the group consisting of the genes UCP2, ACAN, FGF9 and COL11A1, and the level of an expression product of the gene KLF9,
c) identifying the dermal fibroblast of step a) as a fibroblast of the dermo-hypodermic junction when:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 16 (depends on 3)

The in vitro process for preparing a cell model as claimed in claim 3, also comprising a step of identification of a dermal fibroblast as a fibroblast of the dermo-hyperdermic junction, said identification step being prior to said culture step and comprising:
a) providing a biological sample comprising at least one dermal fibroblast,
b) measuring, in the biological sample provided in step a), the level of an expression product of at least one gene selected from the group consisting of the genes UCP2, ACAN, FGF9 and COL11A1, and the level of an expression product of the gene KLF9,
c) identifying the dermal fibroblast of step a) as a fibroblast of the dermo-hypodermic junction when:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 17 (depends on 4)

The in vitro process for preparing a tissue model as claimed in claim 4, also comprising a step of identification of a dermal fibroblast as a fibroblast of the dermo-hyperdermic junction, said identification step being prior to said culture step and comprising:
a) providing a biological sample comprising at least one dermal fibroblast,
b) measuring, in the biological sample provided in step a), the level of an expression product of at least one gene selected from the group consisting of the genes UCP2, ACAN, FGF9 and COL11A1, and the level of an expression product of the gene KLF9,
c) identifying the dermal fibroblast of step a) as a fibroblast of the dermo-hypodermic junction when:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 18 (depends on 5)

The in vitro process for preparing a tissue model as claimed in claim 5, also comprising a step of identification of a dermal fibroblast as a fibroblast of the dermo-hyperdermic junction, said identification step being prior to said culture step and comprising:
a) providing a biological sample comprising at least one dermal fibroblast,
b) measuring, in the biological sample provided in step a), the level of an expression product of at least one gene selected from the group consisting of the genes UCP2, ACAN, FGF9 and COL11A1, and the level of an expression product of the gene KLF9,
c) identifying the dermal fibroblast of step a) as a fibroblast of the dermo-hypodermic junction when:
1) (i) the level of the expression product of the gene UCP2 is decreased relative to a control level,
(ii) the level of the expression product of the gene ACAN is increased relative to a control level,
(iii) the level of the expression product of the gene FGF9 is increased relative to a control level, and/or
(iv) the level of the expression product of the gene COL11A1 is increased relative to a control level,
and
2) the level of the expression product of the gene KLF9 is increased relative to a control level,
wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) being respectively the level of the expression product of the genes UCP2, ACAN, FGF9 and COL11A1 in a dermal fibroblast known to be a papillary fibroblast and the control level of 2) being the level of the expression product of the gene KLF9 in a dermal fibroblast known to be a reticular fibroblast.

### Claim 19 (depends on 2)

An in vitro cell model obtainable according to the process as defined in claim 2.

### Claim 20 (depends on 5)

An in vitro tissue model obtainable according to claim 5.
